Biopharma
ByPfizer’s $10 Billion Innovent Alliance: Is China Now the Epicenter of Next-Gen Cancer Drug Discovery?
Key Highlights A Broad Multidrug Alliance Built for Scale The agreement spans up to 12 programs, eight originating…
J&J’s $1 Billion Firefly Bio Buy: Has Big Pharma Finally Found a Way to Drug the ‘Undruggable’ KRAS?
Key Highlights A Novel Modality for a Notoriously Hard Target At the center of the acquisition is Firefly…
Can a Single Injection Change Everything? Novartis’s Itvisma Wins EU Approval for Broader SMA Population
Key Highlights Closing a Long-Standing Treatment Gap Itvisma’s approval extends gene replacement therapy to an SMA population that…
Can Novartis’s Up to $1.5 Billion Acquisition of Myricx Bio Unlock a New Generation of Cancer-Fighting Antibody-Drug Conjugates?
Key Highlights A Landmark Exit for Early-Stage Science Brandon Capital’s exit from Myricx Bio represents one of its…
Lilly’s U.S. Pricing Play: How Volume Economics Are Rewriting the Growth Story for Zepbound and Mounjaro
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient access, and competitive…
Can a $10 Billion Pipeline Opportunity Help Novartis Outrun Its Entresto Patent Cliff After a $5.94 Billion Profit Beat?
Key Highlights A Landmark Quarter Reinforcing Confidence in Novartis’ Growth Trajectory Novartis’ second-quarter results send an encouraging signal…
